DC
AVDL

Diametric Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Diametric Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,357
Closed -$616K – 388
2025
Q3 		$616K Sell
40,357
-37,166
-48% -$484K 0.23% 110
2025
Q2 		$686K Buy
77,523
+18,590
+32% +$163K 0.37% 78
2025
Q1 		$461K Buy
58,933
+31,637
+116% +$265K 0.55% 55
2024
Q4 		$287K Sell
27,296
-4,893
-15% -$59.4K 0.19% 166
2024
Q3 		$422K Buy
32,189
+11,334
+54% +$173K 0.21% 153
2024
Q2 		$293K Buy
+20,855
New +$340K 0.16% 182
2024
Q1 		– Sell
-35,739
Closed -$505K – 338
2023
Q4 		$505K Buy
+35,739
New +$420K 0.31% 98

Other funds holding AVDL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Diametric Capital's AVDL Position: Q4 2025 in Review

Diametric Capital sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 40,357 shares — an estimated $616K sold.

Diametric Capital first reported a position in AVDL in Q4 2023 and held it in 7 quarters. The position peaked at $686K in Q2 2025. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • Diametric Capital reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Diametric Capital sold 40,357 Avadel Pharmaceuticals shares in Q4 2025, an estimated $616K.
  • Diametric Capital first reported a position in Avadel Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • Diametric Capital's Avadel Pharmaceuticals position peaked at $686K in Q2 2025.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Diametric Capital's 13F filing for Q4 2025, filed 13 Feb 2026.